

**Clinical trial results:****A PHASE III STUDY OF VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) VERSUS VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.****Summary**

EudraCT number	2013-003174-27
Trial protocol	FR
Global end of trial date	12 August 2015

**Results information**

Result version number	v1 (current)
This version publication date	09 August 2022
First version publication date	09 August 2022

**Trial information****Trial identification**

Sponsor protocol code	RC13-0284
-----------------------	-----------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01971658
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	CHU de Nantes
Sponsor organisation address	5 allée de l'Ile Gloriette, Nantes, France, 44 093
Public contact	Département Promotion, CHU de Nantes, 033 253482835, Bp-prom-regl@chu-nantes.fr
Scientific contact	Département Promotion, CHU de Nantes, 033 253482835, Bp-prom-regl@chu-nantes.fr

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	18 May 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	12 August 2015
Global end of trial reached?	Yes
Global end of trial date	12 August 2015
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

The primary objective of this study is to compare the VGPR rate achieved with four courses of VTD with that achieved with four courses of VCD

Protection of trial subjects:

- Prophylaxis of opportunistic infections: Bactrim Forte, oral enicillin or macrolide (for cases of penicillin allergy), Acyclovir or Valacyclovir (for antiviral prophylaxis)
- Bisphosphonate (for bone lesions or osteopaenia), according to centre policy
- Recombinant erythropoietin (if haemoglobin levels <11g/dL), according to centre policy

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 November 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	France: 358
Worldwide total number of subjects	358
EEA total number of subjects	358

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	333
From 65 to 84 years	25

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

358 patients were included from 06/11/2013 to 18/02/2015 in 58 French centers / 60 open.  
340 patients were randomized arm VCD 170 ans arm VTD 170 patients

### Pre-assignment

Screening details:

inclusion criteria - Patients newly diagnosed with symptomatic Multiple Myeloma patient, must have measurable disease by serum M-protein  $\geq 10$  g/L and/or urine M-protein  $\geq 200$ mg/day or Serum Free Light Chain MM (Freelite)

### Pre-assignment period milestones

Number of subjects started	358
Number of subjects completed	340

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	patient not having the inclusion criteria: 18
----------------------------	---

### Period 1

Period 1 title	essais global (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	ARM VCD

Arm description:

For arm B:

1- Induction therapy : 4 cycles of VCD

Each cycle : 21 days

Each cycle comprises:

o Cyclophosphamide 500 mg/m<sup>2</sup>/d, PO D1, 8, 15

o Velcade® 1.3 mg/m<sup>2</sup>/d, SC D1, 4, 8 and 11

o Dexamethasone 40 mg/d, PO D1 to 4, D9 to 12

Arm type	Active comparator
Investigational medicinal product name	Velcade
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

1.3 mg/m<sup>2</sup> subcutaneously on Days 1, 4, 8, and 11, followed by a 10-day rest period (Days 12 to 21)

Investigational medicinal product name	Cyclophosphamide
Investigational medicinal product code	
Other name	Endoxan
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

CYCLOPHOSPHAMIDE 500 mg/m<sup>2</sup> orally on Days 1, 8 and 15

Investigational medicinal product name	Dexaméthasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Buccal tablet
Routes of administration	Oral use
Dosage and administration details: DEXAMETHASONE 40 mg/day orally on Days 1-4 and 9-12	
<b>Arm title</b>	ARM VTD

Arm description:

For arm A:

Induction therapy : 4 cycles of VTD

Each cycle : 21 days

Each cycle comprises:

o Thalidomide® 100 mg/d, PO D1 to J21

o Velcade® 1.3 mg/m<sup>2</sup>/d, SC D1, 4, 8 and 11

o Dexamethasone 40 mg/d, PO D1 to 4, D9 to 12

Arm type	Active comparator
Investigational medicinal product name	Thalidomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

100 mg/day orally on days 1 to 21

Investigational medicinal product name	Velcade
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

1.3 mg/m<sup>2</sup> subcutaneously on Days 1, 4, 8, and 11, followed by a 10-day rest period (Days 12 to 21)

Investigational medicinal product name	Dexaméthasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Buccal tablet
Routes of administration	Oral use

Dosage and administration details:

DEXAMETHASONE 40 mg/day orally on Days 1 to 4 and 9 to 12

<b>Number of subjects in period 1<sup>[1]</sup></b>	ARM VCD	ARM VTD
Started	170	170
Completed	154	157
Not completed	16	13
Physician decision	6	1
Consent withdrawn by subject	-	1
death	3	2
progression	-	3

Adverse event, non-fatal	3	5
Progreseion	1	-
Protocol deviation	3	1

---

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 358 people were included in the Research and 340 randomized

## Baseline characteristics

### Reporting groups

Reporting group title	ARM VCD
-----------------------	---------

Reporting group description:

For arm B:

1- Induction therapy : 4 cycles of VCD

Each cycle : 21 days

Each cycle comprises:

o Cyclophosphamide 500 mg/m<sup>2</sup>/d, PO D1, 8, 15

o Velcade® 1.3 mg/m<sup>2</sup>/d, SC D1, 4, 8 and 11

o Dexamethasone 40 mg/d, PO D1 to 4, D9 to 12

Reporting group title	ARM VTD
-----------------------	---------

Reporting group description:

For arm A:

Induction therapy : 4 cycles of VTD

Each cycle : 21 days

Each cycle comprises:

o Thalidomide® 100 mg/d, PO D1 to J21

o Velcade® 1.3 mg/m<sup>2</sup>/d, SC D1, 4, 8 and 11

o Dexamethasone 40 mg/d, PO D1 to 4, D9 to 12

Reporting group values	ARM VCD	ARM VTD	Total
Number of subjects	170	170	340
Age categorical			
Units: Subjects			
Adults (18-64 years)	155	161	316
From 65-84 years	15	9	24
Age continuous			
Units: years			
median	60	59	
full range (min-max)	26 to 65	34 to 65	-
Gender categorical			
Units: Subjects			
Female	61	67	128
Male	109	103	212

## End points

### End points reporting groups

Reporting group title	ARM VCD
Reporting group description:	
For arm B:	
1- Induction therapy : 4 cycles of VCD	
Each cycle : 21 days	
Each cycle comprises:	
o Cyclophosphamide 500 mg/m <sup>2</sup> /d, PO D1, 8, 15	
o Velcade® 1.3 mg/m <sup>2</sup> /d, SC D1, 4, 8 and 11	
o Dexamethasone 40 mg/d, PO D1 to 4, D9 to 12	
Reporting group title	ARM VTD
Reporting group description:	
For arm A:	
Induction therapy : 4 cycles of VTD	
Each cycle : 21 days	
Each cycle comprises:	
o Thalidomide® 100 mg/d, PO D1 to J21	
o Velcade® 1.3 mg/m <sup>2</sup> /d, SC D1, 4, 8 and 11	
o Dexamethasone 40 mg/d, PO D1 to 4, D9 to 12	

### Primary: Compare the VGPR rate

End point title	Compare the VGPR rate
End point description:	
The primary efficacy endpoint is VGPR rate obtained with VTD or VTC at the end of induction phase based on ITT population.	
This analysis will use the Cochran-Mantel-Haenszel chi-square test, adjusted for the stratification factors.	
The 2-sided 95% confidence intervals for the response rate for each treatment group, the 2-sided 95% confidence interval for the difference in response rate between the two groups, and the p-value will be presented.	
End point type	Primary
End point timeframe:	
5 months	

End point values	ARM VCD	ARM VTD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	169	169		
Units: percentage				
number (not applicable)	56.2	66.3		

### Statistical analyses

Statistical analysis title	Compare the VGPR rate
Statistical analysis description:	
The primary efficacy endpoint is VGPR rate obtained with VTD or VTC at the end of induction phase based on ITT population.	



This analysis will use the Cochran-Mantel-Haenszel chi-square test, adjusted for the stratification factors.

The 2-sided 95% confidence intervals for the response rate for each treatment group, the 2-sided 95% confidence interval for the difference in response rate between the two groups, and the p-value will be presented.

Comparison groups	ARM VTD v ARM VCD
Number of subjects included in analysis	338
Analysis specification	Pre-specified
Analysis type	other <sup>[1]</sup>
P-value	= 0.05 <sup>[2]</sup>
Method	Khi <sup>2</sup> Cochran-Mantel-Haenszel

Notes:

[1] - In the ITT population, 66.3% of patients in the VTD arm achieved at least one VGPR versus 56.2% in the VCD arm (P=0.05). The difference in VGRR rate (primary objective) between the VTD and VCD arms was 10.1% (95% CI, 1% to 18%)

In the PP per-protocol analysis, the VGPR rate was also significantly higher in the VTD arm (70.7% vs 60.4%, P 0.05, difference 10.3%, 95% CI 2% to 21%).

[2] - In the ITT population p=0.05

In the PP per-protocol analysis P=0.05

## Secondary: Quality of stem cell collection

End point title	Quality of stem cell collection
End point description:	
Stem cell collection, starting 1 week after cycle 3: cyclophosphamide 3 g/m <sup>2</sup> followed by G-CSF (5 µg/kg/day)	
End point type	Secondary
End point timeframe:	
3 cycle	

End point values	ARM VCD	ARM VTD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	155	159		
Units: 10X6 cellules / kg				
number (not applicable)	9.2	10.7		

## Statistical analyses

<b>Statistical analysis title</b>	Stem cell collection
Comparison groups	ARM VTD v ARM VCD
Number of subjects included in analysis	314
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.05 <sup>[3]</sup>
Method	Cochran-Mantel-Haenszel chisquare test,

Notes:

[3] - Le nombre médian de CD34+ collecté étaient de 10.7 X 10<sup>6</sup> cellules / kg dans le bras VTD versus 9.2 X 10<sup>6</sup> cellule/kg dans le bras VCD (P=0.05).

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

5 cycles

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

### Reporting groups

Reporting group title	ARM VCD
-----------------------	---------

Reporting group description:

For arm B:

1- Induction therapy : 4 cycles of VCD

Each cycle : 21 days

Each cycle comprises:

o Cyclophosphamide 500 mg/m<sup>2</sup>/d, PO D1, 8, 15

o Velcade® 1.3 mg/m<sup>2</sup>/d, SC D1, 4, 8 and 11

o Dexamethasone 40 mg/d, PO D1 to 4, D9 to 12

Reporting group title	ARM VTD
-----------------------	---------

Reporting group description:

For arm A:

Induction therapy : 4 cycles of VTD

Each cycle : 21 days

Each cycle comprises:

o Thalidomide® 100 mg/d, PO D1 to J21

o Velcade® 1.3 mg/m<sup>2</sup>/d, SC D1, 4, 8 and 11

o Dexamethasone 40 mg/d, PO D1 to 4, D9 to 12

Serious adverse events	ARM VCD	ARM VTD	
Total subjects affected by serious adverse events			
subjects affected / exposed	63 / 167 (37.72%)	61 / 167 (36.53%)	
number of deaths (all causes)	3	2	
number of deaths resulting from adverse events	3	2	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Refractory anaemia with an excess of blasts			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma			

subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant pleural effusion			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic neoplasm			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parathyroid tumour benign			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			
subjects affected / exposed	2 / 167 (1.20%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis superficial			

subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cryoglobulinaemia			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Parathyroidectomy			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthermia			
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injection site erythema			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Oral administration complication subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration subjects affected / exposed	3 / 167 (1.80%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	3 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Hypoxia subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism subjects affected / exposed	3 / 167 (1.80%)	4 / 167 (2.40%)	
occurrences causally related to treatment / all	2 / 3	4 / 4	
deaths causally related to treatment / all	0 / 0	1 / 1	
Bronchial obstruction subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pleural effusion subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
mania			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Lipase increased			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal myelogram abnormal			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Drug administration error			
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medication error			
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture			

subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug dose omission			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inappropriate schedule of drug administration			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incorrect dose administered			
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incorrect drug administration duration			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional product misuse			
subjects affected / exposed	2 / 167 (1.20%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax traumatic			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural complication			

subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block second degree			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Cardiac failure			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive heart disease			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular extrasystoles			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			



subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebellar syndrome			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coma			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extrapyramidal disorder			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxic-ischaemic encephalopathy			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy peripheral			
subjects affected / exposed	2 / 167 (1.20%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral sensorimotor neuropathy			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brown-Sequard syndrome			

subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperaesthesia			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle contractions involuntary			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuralgia			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral motor neuropathy			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	2 / 167 (1.20%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone marrow failure			

subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile bone marrow aplasia			
subjects affected / exposed	7 / 167 (4.19%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	7 / 7	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	4 / 167 (2.40%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	4 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombotic microangiopathy			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Ear and labyrinth disorders			
Ear pain			

subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticular perforation			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal necrosis			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal toxicity			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumoperitoneum			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			

subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorder			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular injury			
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Acute generalised exanthematous pustulosis			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Toxic skin eruption subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Cystitis haemorrhagic subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure acute subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	0 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain subjects affected / exposed	5 / 167 (2.99%)	3 / 167 (1.80%)	
occurrences causally related to treatment / all	2 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone pain subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Spinal compression fracture			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Sternal fracture			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bacterial sepsis			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	4 / 167 (2.40%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	3 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumonia			
subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonic abscess			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia infection			

subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile infection			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis jiroveci pneumonia			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia escherichia			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia haemophilus			



subjects affected / exposed	3 / 167 (1.80%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal			
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis Escherichia coli			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	2 / 167 (1.20%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	3 / 167 (1.80%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	2 / 3	1 / 2	
deaths causally related to treatment / all	2 / 2	0 / 0	
Staphylococcal infection			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stenotrophomonas infection			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis septic			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			

subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	9 / 167 (5.39%)	2 / 167 (1.20%)	
occurrences causally related to treatment / all	8 / 9	2 / 2	
deaths causally related to treatment / all	1 / 1	0 / 0	
Anal fistula infection			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 167 (0.00%)	3 / 167 (1.80%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercreatinaemia			

subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hypocalcaemia</b>			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	ARM VCD	ARM VTD	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	167 / 167 (100.00%)	167 / 167 (100.00%)	
<b>Vascular disorders</b>			
Deep vein thrombosis			
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)	
occurrences (all)	0	2	
Flushing			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
Hypertension			
subjects affected / exposed	4 / 167 (2.40%)	7 / 167 (4.19%)	
occurrences (all)	4	8	
Hot flush			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Hypotension			
subjects affected / exposed	2 / 167 (1.20%)	1 / 167 (0.60%)	
occurrences (all)	2	1	
Orthostatic hypotension			
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)	
occurrences (all)	2	0	
Phlebitis superficial			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	

Thrombosis subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Venous thrombosis subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	1 / 167 (0.60%) 2	
Surgical and medical procedures			
Cementoplasty subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Oophorectomy subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Tooth extraction subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	1 / 167 (0.60%) 1	
Vertebroplasty subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Phlebitis subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 2	
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	43 / 167 (25.75%) 49	35 / 167 (20.96%) 38	
Chest discomfort subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	2 / 167 (1.20%) 2	
Chest pain subjects affected / exposed occurrences (all)	5 / 167 (2.99%) 5	5 / 167 (2.99%) 5	
Chills subjects affected / exposed occurrences (all)	3 / 167 (1.80%) 3	2 / 167 (1.20%) 2	
Face oedema			

subjects affected / exposed	0 / 167 (0.00%)	3 / 167 (1.80%)
occurrences (all)	0	3
Fatigue		
subjects affected / exposed	1 / 167 (0.60%)	3 / 167 (1.80%)
occurrences (all)	1	3
Feeling jittery		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
General physical health deterioration		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Hyperthermia		
subjects affected / exposed	2 / 167 (1.20%)	3 / 167 (1.80%)
occurrences (all)	2	3
Inflammation		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Influenza like illness		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Injection site erythema		
subjects affected / exposed	2 / 167 (1.20%)	1 / 167 (0.60%)
occurrences (all)	2	1
Injection site haemorrhage		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Injection site reaction		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Local swelling		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Localised oedema		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Malaise		

subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
Mucosal dryness			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Mucosal inflammation			
subjects affected / exposed	2 / 167 (1.20%)	2 / 167 (1.20%)	
occurrences (all)	2	2	
Mucositis			
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)	
occurrences (all)	2	0	
Non-cardiac chest pain			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Oedema			
subjects affected / exposed	2 / 167 (1.20%)	3 / 167 (1.80%)	
occurrences (all)	2	3	
Oedema peripheral			
subjects affected / exposed	18 / 167 (10.78%)	31 / 167 (18.56%)	
occurrences (all)	20	34	
Pain			
subjects affected / exposed	2 / 167 (1.20%)	6 / 167 (3.59%)	
occurrences (all)	2	6	
Pyrexia			
subjects affected / exposed	18 / 167 (10.78%)	11 / 167 (6.59%)	
occurrences (all)	19	11	
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 167 (0.00%)	3 / 167 (1.80%)	
occurrences (all)	0	3	
Hypersensitivity			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Seasonal allergy			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	

Reproductive system and breast disorders			
Acquired phimosis			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Benign prostatic hyperplasia			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Vulvovaginal discomfort			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Respiratory, thoracic and mediastinal disorders			
Asthmatic crisis			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Bronchospasm			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Cough			
subjects affected / exposed	11 / 167 (6.59%)	9 / 167 (5.39%)	
occurrences (all)	11	9	
Dysphonia			
subjects affected / exposed	4 / 167 (2.40%)	0 / 167 (0.00%)	
occurrences (all)	4	0	
Dyspnoea			
subjects affected / exposed	6 / 167 (3.59%)	8 / 167 (4.79%)	
occurrences (all)	7	10	
Dyspnoea exertional			
subjects affected / exposed	3 / 167 (1.80%)	2 / 167 (1.20%)	
occurrences (all)	3	2	
Epistaxis			
subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)	
occurrences (all)	1	2	

Hiccups			
subjects affected / exposed	4 / 167 (2.40%)	3 / 167 (1.80%)	
occurrences (all)	4	3	
Oropharyngeal pain			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Pleurisy			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Productive cough			
subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)	
occurrences (all)	1	2	
Pulmonary hypertension			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Pulmonary embolism			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Respiratory failure			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Rhinorrhoea			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Tachypnoea			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Wheezing			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Psychiatric disorders			
Aggression			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
affective disorder			



subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Anxiety		
subjects affected / exposed	9 / 167 (5.39%)	12 / 167 (7.19%)
occurrences (all)	9	12
Confusional state		
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)
occurrences (all)	0	2
Depression		
subjects affected / exposed	3 / 167 (1.80%)	3 / 167 (1.80%)
occurrences (all)	3	3
Hallucination, visual		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
hyperexcitation		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
hypomania		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Insomnia		
subjects affected / exposed	10 / 167 (5.99%)	7 / 167 (4.19%)
occurrences (all)	11	8
Mood altered		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
nervousness		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Nightmare		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Sleep disorder		
subjects affected / exposed	5 / 167 (2.99%)	3 / 167 (1.80%)
occurrences (all)	5	3
Logorrhoea		

subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Psychiatric symptom			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Investigations			
Lymphocyte count decreased			
subjects affected / exposed	2 / 167 (1.20%)	1 / 167 (0.60%)	
occurrences (all)	3	1	
Neutrophil count decreased			
subjects affected / exposed	6 / 167 (3.59%)	7 / 167 (4.19%)	
occurrences (all)	8	7	
Platelet count decreased			
subjects affected / exposed	2 / 167 (1.20%)	1 / 167 (0.60%)	
occurrences (all)	2	1	
White blood cell count decreased			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
Angina pectoris			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Alanine aminotransferase decreased			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Alanine aminotransferase increased			
subjects affected / exposed	0 / 167 (0.00%)	4 / 167 (2.40%)	
occurrences (all)	0	4	
Aspartate aminotransferase decreased			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Gamma-glutamyltransferase increased			

subjects affected / exposed	0 / 167 (0.00%)	3 / 167 (1.80%)	
occurrences (all)	0	5	
Blood creatinine increased			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
Blood phosphorus decreased			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Blood alkaline phosphatase increased			
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)	
occurrences (all)	2	0	
C-reactive protein increased			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Staphylococcus test positive			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Weight decreased			
subjects affected / exposed	5 / 167 (2.99%)	1 / 167 (0.60%)	
occurrences (all)	5	1	
Weight increased			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
Injury, poisoning and procedural complications			
fall			
subjects affected / exposed	2 / 167 (1.20%)	2 / 167 (1.20%)	
occurrences (all)	2	2	
Intentional product misuse			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Fracture			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Subcutaneous haematoma			

subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Tooth fracture subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Cardiac disorders			
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Bradycardia subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	1 / 167 (0.60%) 1	
Palpitations subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	1 / 167 (0.60%) 1	
Tachycardia subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	4 / 167 (2.40%) 4	
Sinus tachycardia subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Nervous system disorders			
Chest pain subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Ageusia subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Cognitive disorder subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	1 / 167 (0.60%) 1	
Dizziness subjects affected / exposed occurrences (all)	2 / 167 (1.20%) 2	4 / 167 (2.40%) 4	
Dysaesthesia			

subjects affected / exposed	4 / 167 (2.40%)	3 / 167 (1.80%)
occurrences (all)	4	3
Dysgeusia		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Extrapyramidal disorder		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Headache		
subjects affected / exposed	13 / 167 (7.78%)	9 / 167 (5.39%)
occurrences (all)	14	10
Hypoaesthesia		
subjects affected / exposed	3 / 167 (1.80%)	3 / 167 (1.80%)
occurrences (all)	3	3
Migraine		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Neuralgia		
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)
occurrences (all)	0	2
Neuropathy peripheral		
subjects affected / exposed	40 / 167 (23.95%)	63 / 167 (37.72%)
occurrences (all)	51	82
Neurotoxicity		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Optic neuritis		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Paraesthesia		
subjects affected / exposed	18 / 167 (10.78%)	25 / 167 (14.97%)
occurrences (all)	18	28
Peripheral motor neuropathy		
subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)
occurrences (all)	1	2
Peripheral nerve palsy		

subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
Peripheral sensorimotor neuropathy			
subjects affected / exposed	0 / 167 (0.00%)	3 / 167 (1.80%)	
occurrences (all)	0	6	
Polyneuropathy			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Presyncope			
subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)	
occurrences (all)	1	2	
Radicular syndrome			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Sciatica			
subjects affected / exposed	4 / 167 (2.40%)	1 / 167 (0.60%)	
occurrences (all)	4	1	
Somnolence			
subjects affected / exposed	1 / 167 (0.60%)	3 / 167 (1.80%)	
occurrences (all)	1	3	
syncope			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
tremor			
subjects affected / exposed	2 / 167 (1.20%)	8 / 167 (4.79%)	
occurrences (all)	2	9	
Agitation			
subjects affected / exposed	6 / 167 (3.59%)	3 / 167 (1.80%)	
occurrences (all)	6	3	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	26 / 167 (15.57%)	22 / 167 (13.17%)	
occurrences (all)	37	22	
Bone marrow failure			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	

Febrile bone marrow aplasia subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Febrile neutropenia subjects affected / exposed occurrences (all)	4 / 167 (2.40%) 4	1 / 167 (0.60%) 1	
Leukopenia subjects affected / exposed occurrences (all)	12 / 167 (7.19%) 16	5 / 167 (2.99%) 5	
Leukocytosis subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Lymphopenia subjects affected / exposed occurrences (all)	53 / 167 (31.74%) 135	43 / 167 (25.75%) 72	
Neutropenia subjects affected / exposed occurrences (all)	42 / 167 (25.15%) 72	21 / 167 (12.57%) 29	
Thrombocytopenia subjects affected / exposed occurrences (all)	19 / 167 (11.38%) 30	11 / 167 (6.59%) 11	
Ear and labyrinth disorders			
Hypoacusis subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Tinnitus subjects affected / exposed occurrences (all)	2 / 167 (1.20%) 2	2 / 167 (1.20%) 2	
Vertigo subjects affected / exposed occurrences (all)	3 / 167 (1.80%) 3	4 / 167 (2.40%) 4	
Acute vestibular syndrome subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Ear pain			

subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
hearing impaired			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Eye disorders			
Chalazion			
subjects affected / exposed	3 / 167 (1.80%)	1 / 167 (0.60%)	
occurrences (all)	3	1	
Chromatopsia			
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)	
occurrences (all)	0	2	
Conjunctival haemorrhage			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Eyelid oedema			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Keratitis			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Uveitis			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Vision blurred			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
Visual acuity reduced			
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)	
occurrences (all)	0	2	
Visual impairment			
subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)	
occurrences (all)	1	2	
Eye pruritus			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	



Miosis			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Photophobia			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	2 / 167 (1.20%)	1 / 167 (0.60%)	
occurrences (all)	2	1	
Abdominal pain			
subjects affected / exposed	4 / 167 (2.40%)	5 / 167 (2.99%)	
occurrences (all)	4	5	
Abdominal pain upper			
subjects affected / exposed	7 / 167 (4.19%)	5 / 167 (2.99%)	
occurrences (all)	7	5	
aphthous stomatitis			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
Constipation			
subjects affected / exposed	35 / 167 (20.96%)	59 / 167 (35.33%)	
occurrences (all)	39	68	
Diarrhoea			
subjects affected / exposed	21 / 167 (12.57%)	8 / 167 (4.79%)	
occurrences (all)	21	8	
Dry mouth			
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)	
occurrences (all)	0	2	
Dysgeusia			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
Dyspepsia			
subjects affected / exposed	6 / 167 (3.59%)	5 / 167 (2.99%)	
occurrences (all)	6	5	
Diverticulum intestinal			

subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Duodenogastric reflux		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Flatulence		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Gastrointestinal disorder		
subjects affected / exposed	4 / 167 (2.40%)	2 / 167 (1.20%)
occurrences (all)	4	2
dysphagia		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Eructation		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Gastritis		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Gastrointestinal motility disorder		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Gastroesophageal reflux disease		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Impaired gastric emptying		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Intestinal dilatation		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Mouth ulceration		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	2	0
Nausea		

subjects affected / exposed	47 / 167 (28.14%)	39 / 167 (23.35%)	
occurrences (all)	54	43	
Oesophagitis			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Oral discomfort			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Rectal haemorrhage			
subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)	
occurrences (all)	1	2	
Rectal prolapse			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Stomatitis			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Vomiting			
subjects affected / exposed	16 / 167 (9.58%)	12 / 167 (7.19%)	
occurrences (all)	18	12	
Tongue discolouration			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Tooth demineralisation			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
Hepatocellular injury			
subjects affected / exposed	0 / 167 (0.00%)	6 / 167 (3.59%)	
occurrences (all)	0	6	
Cholelithiasis			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Drug-induced liver injury			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	

Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	3 / 167 (1.80%)	6 / 167 (3.59%)	
occurrences (all)	3	6	
Decubitus ulcer			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Dermatitis acneiform			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Dermatitis allergic			
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)	
occurrences (all)	0	2	
Dermatitis contact			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Dry skin			
subjects affected / exposed	2 / 167 (1.20%)	3 / 167 (1.80%)	
occurrences (all)	2	3	
Ecchymosis			
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)	
occurrences (all)	0	1	
Eczema			
subjects affected / exposed	0 / 167 (0.00%)	3 / 167 (1.80%)	
occurrences (all)	0	3	
Erythema			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
Hand dermatitis			
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)	
occurrences (all)	1	1	
Hidradenitis			
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)	
occurrences (all)	1	0	
Hyperhidrosis			

subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Macule		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Mucocutaneous rash		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Nail disorder		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Night sweats		
subjects affected / exposed	2 / 167 (1.20%)	1 / 167 (0.60%)
occurrences (all)	2	1
Pruritus		
subjects affected / exposed	2 / 167 (1.20%)	4 / 167 (2.40%)
occurrences (all)	2	4
Rash		
subjects affected / exposed	12 / 167 (7.19%)	14 / 167 (8.38%)
occurrences (all)	13	14
Rash maculo-papular		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Rash papular		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Rash pruritic		
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)
occurrences (all)	0	2
Skin disorder		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Skin reaction		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Swelling face		

subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	1 / 167 (0.60%) 1	
Toxic skin eruption subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	2 / 167 (1.20%) 2	
Urticaria subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	1 / 167 (0.60%) 1	
Renal and urinary disorders			
Acute kidney injury subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Bladder discomfort subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Cystitis haemorrhagic subjects affected / exposed occurrences (all)	2 / 167 (1.20%) 2	0 / 167 (0.00%) 0	
Dysuria subjects affected / exposed occurrences (all)	4 / 167 (2.40%) 4	1 / 167 (0.60%) 1	
Haematuria subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Nocturia subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Oliguria subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Pollakiuria subjects affected / exposed occurrences (all)	2 / 167 (1.20%) 2	0 / 167 (0.00%) 0	
Proteinuria subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	

Renal failure subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	2 / 167 (1.20%) 2	
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Endocrine disorders Cushingoid subjects affected / exposed occurrences (all)	2 / 167 (1.20%) 2	0 / 167 (0.00%) 0	
Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	1 / 167 (0.60%) 1	
Hyperparathyroidism subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	2 / 167 (1.20%) 2	3 / 167 (1.80%) 3	
back pain subjects affected / exposed occurrences (all)	25 / 167 (14.97%) 25	22 / 167 (13.17%) 22	
Bone lesion subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Bone pain subjects affected / exposed occurrences (all)	8 / 167 (4.79%) 9	7 / 167 (4.19%) 7	
Enthesopathy subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Groin pain subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	1 / 167 (0.60%) 1	
Muscle spasms			

subjects affected / exposed	3 / 167 (1.80%)	3 / 167 (1.80%)
occurrences (all)	3	3
Musculoskeletal chest pain		
subjects affected / exposed	4 / 167 (2.40%)	7 / 167 (4.19%)
occurrences (all)	4	7
Musculoskeletal discomfort		
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)
occurrences (all)	2	0
Myalgia		
subjects affected / exposed	5 / 167 (2.99%)	3 / 167 (1.80%)
occurrences (all)	5	3
Neck pain		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Osteoporosis		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Osteonecrosis		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Pain in extremity		
subjects affected / exposed	11 / 167 (6.59%)	9 / 167 (5.39%)
occurrences (all)	11	11
Pathological fracture		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Spinal osteoarthritis		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Spinal pain		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Tendonitis		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Synovial cyst		



subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Amnesia subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Aphonia subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Balance disorder subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Infections and infestations Acute sinusitis subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Bacterial prostatitis subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
BK virus infection cystitis subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Bronchitis subjects affected / exposed occurrences (all)	13 / 167 (7.78%) 13	17 / 167 (10.18%) 18	
Bronchopulmonary aspergillosis subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Cellulitis subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Conjunctivitis subjects affected / exposed occurrences (all)	3 / 167 (1.80%) 3	1 / 167 (0.60%) 2	
Cystitis subjects affected / exposed occurrences (all)	5 / 167 (2.99%) 5	1 / 167 (0.60%) 1	

Cytomegalovirus infection		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Device related infection		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Ear infection viral		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Erysipelas		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	2
Escherichia infection		
subjects affected / exposed	0 / 167 (0.00%)	3 / 167 (1.80%)
occurrences (all)	0	3
Escherichia vaginitis		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Folliculitis		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Fungal skin infection		
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)
occurrences (all)	2	0
Gastrointestinal candidiasis		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Genital infection fungal		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Hordeolum		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Haemorrhoid infection		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1

Infected cyst		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
infection		
subjects affected / exposed	0 / 167 (0.00%)	3 / 167 (1.80%)
occurrences (all)	0	4
infectious colitis		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Influenza		
subjects affected / exposed	4 / 167 (2.40%)	2 / 167 (1.20%)
occurrences (all)	4	2
Laryngitis		
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)
occurrences (all)	1	1
Localised infection		
subjects affected / exposed	2 / 167 (1.20%)	0 / 167 (0.00%)
occurrences (all)	2	0
Lung infection		
subjects affected / exposed	3 / 167 (1.80%)	0 / 167 (0.00%)
occurrences (all)	3	0
Nasal herpes		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Nasopharyngitis		
subjects affected / exposed	4 / 167 (2.40%)	8 / 167 (4.79%)
occurrences (all)	4	8
Oral candidiasis		
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)
occurrences (all)	0	2
Oral fungal infection		
subjects affected / exposed	1 / 167 (0.60%)	4 / 167 (2.40%)
occurrences (all)	1	4
Osteitis		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1

ophtalmic herpes zoster		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Orchitis		
subjects affected / exposed	3 / 167 (1.80%)	0 / 167 (0.00%)
occurrences (all)	3	0
Pharyngitis		
subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)
occurrences (all)	1	2
Pneumococcal sepsis		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Pneumonia		
subjects affected / exposed	2 / 167 (1.20%)	2 / 167 (1.20%)
occurrences (all)	2	2
PROSTATITIS		
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)
occurrences (all)	1	1
Prostatitis Escherichia coli		
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)
occurrences (all)	1	1
Puncture site infection		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Rhinitis		
subjects affected / exposed	2 / 167 (1.20%)	4 / 167 (2.40%)
occurrences (all)	2	4
Salmonellosis		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Sepsis		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Sinusitis		
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)
occurrences (all)	0	2

Staphylococcal bacteraemia		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Subcutaneous abscess		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Staphylococcal sepsis		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Streptococcal sepsis		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Tongue fungal infection		
subjects affected / exposed	0 / 167 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	1
Tonsillitis		
subjects affected / exposed	1 / 167 (0.60%)	2 / 167 (1.20%)
occurrences (all)	1	2
Tooth abscess		
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)
occurrences (all)	1	1
Tooth infection		
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)
occurrences (all)	1	1
Upper respiratory tract infection		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Urinary tract infection		
subjects affected / exposed	7 / 167 (4.19%)	1 / 167 (0.60%)
occurrences (all)	7	1
Vaginal infection		
subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Vulvovaginal mycotic infection		
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)
occurrences (all)	0	2

Thermal burn subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Metabolism and nutrition disorders			
Alkalosis subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Appetite disorder subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Cell death subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	0 / 167 (0.00%) 0	
Decreased appetite subjects affected / exposed occurrences (all)	3 / 167 (1.80%) 3	4 / 167 (2.40%) 4	
Dehydration subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
gout subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	2 / 167 (1.20%) 2	
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	4 / 167 (2.40%) 4	
Hyperglycaemia subjects affected / exposed occurrences (all)	2 / 167 (1.20%) 2	3 / 167 (1.80%) 3	
Hyperphagia subjects affected / exposed occurrences (all)	1 / 167 (0.60%) 1	1 / 167 (0.60%) 1	
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 167 (0.00%) 0	1 / 167 (0.60%) 1	
Hyperuricaemia			

subjects affected / exposed	1 / 167 (0.60%)	0 / 167 (0.00%)
occurrences (all)	1	0
Hypoalbuminaemia		
subjects affected / exposed	1 / 167 (0.60%)	1 / 167 (0.60%)
occurrences (all)	1	1
Hypocalcaemia		
subjects affected / exposed	4 / 167 (2.40%)	0 / 167 (0.00%)
occurrences (all)	4	0
Hypokalaemia		
subjects affected / exposed	2 / 167 (1.20%)	4 / 167 (2.40%)
occurrences (all)	2	4
Hypomagnesemia		
subjects affected / exposed	1 / 167 (0.60%)	3 / 167 (1.80%)
occurrences (all)	1	3
Hyponatraemia		
subjects affected / exposed	0 / 167 (0.00%)	4 / 167 (2.40%)
occurrences (all)	0	5
HYPOPHOSPHATEMIE		
subjects affected / exposed	2 / 167 (1.20%)	4 / 167 (2.40%)
occurrences (all)	2	5
Limb discomfort		
subjects affected / exposed	0 / 167 (0.00%)	2 / 167 (1.20%)
occurrences (all)	0	2
Musculoskeletal pain		
subjects affected / exposed	2 / 167 (1.20%)	5 / 167 (2.99%)
occurrences (all)	2	5

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 July 2014	augmentation du nombre de centre, modification critère exclusion inclusion, précision sur le dose de G-CSF, ajout du droit de participer à l'étude AMG 162, précision sur la prise de Velcade en fonction du poids, sur les dispensations de Cyclophosphamide, mise à jour des toxicités du cyclophosphamide, précision sur les examens fait au screeninig, modification des données de rando, précision des délais pour réaliser les examens biologiques, modification de la quantité de sang à prélever pour analyses de cytogénétique et analyses bioschiliques, mise à jour de l'adresse de l'unité génomique de Toulouse
04 December 2014	prolongation de la période de recrutement
07 May 2015	prolongation de la période de suivi de l'étude (de 2 mois), changement de l'investigateur principal du centre de Poitiers

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/27002117>